Short-Term JAK-STATi Use for Dermatologic Conditions Not Linked to Higher MACE, VTE Risk
Rheumatology Advisor,
There appears to be no increased risk for major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) among…
There appears to be no increased risk for major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) among…
皮膚疾患へのJAKで心血管疾患リスク上昇せず|皮膚|アレルギー_循環器_臨床医学_薬剤情報|医療ニュース|Medical Tribune メタ解析で短期投与のリスクを検討 2024年02月20日 05:05 172名の医師が参考になったと回答 ©…
JAK inhibitors can safely be used over the short-term in dermatology patients, with no evidence of increase in risk of…
There is insufficient evidence to indicate that drugs targeting the JAK-STAT (Janus Kinase-Signal Transducer and Activator of…